Antithrombotic Treatment in COVID-19

Publication Date: July 5, 2022
Last Updated: August 9, 2022


3.1 Antithrombotic therapy for non-hospitalized patients

In non-hospitalized patients with symptomatic COVID-19, initiation of antiplatelet therapy is not effective to reduce risk of hospitalization, arterial or venous thrombosis, or mortality. (III - No Benefit, B-R)

Tables and Figures

TABLE 1. Dose levels of the anticoagulants used in the studies cited in the guideline

Having trouble viewing table?
Drug Prophylactic Intermediate Therapeutic
UFH 000 U SQ BID or TID 7500 U SQ BID or TID Intravenous, adjusted to APTT or anti-Xa
LMWH Enoxaparin 40 mg SQ QD, dalteparin 5000 IU SQ QD, tinzaparin 4500 IU SQ QD, bemiparin 3500 IU SQ QD Enoxaparin 40 mg SQ BID or 80 mg SQ QD, or 0.5 mg/kg SQ QD Enoxaparin 1 mg/kg SQ BID, dalteparin 200 IU/kg SQ QD, tinzaparin 175 IU/kg SQ QD, bemiparin 115 IU/kg SQ QD
DOAC Rivaroxaban 10 mg PO QD, apixaban 2.5 mg PO BID Not applicable Rivaroxaban 20 mg PO QD, apixaban 5 mg PO BID



Antithrombotic Treatment in COVID-19

Authoring Organization